GlassScriptPhysician profile
Monte R Swanson
NPI 1659665396
$3,596.82
in general payments reported to CMS, 2019-2025
31 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $451 · 2021: $662 · 2022: $636 · 2023: $598 · 2024: $351 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,043.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $743.89 | 2019-2024 | Trelegy Ellipta, Arexvy, Rotarix |
| Novo Nordisk INC | $346.87 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $296.05 | 2020-2023 | Steglatro, Belsomra, Gardasil 9 |
| Abbvie INC. | $216.74 | 2020-2025 | Vraylar |
| Pfizer INC. | $148.44 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $101.57 | 2019-2022 | |
| Lilly USA, LLC | $64.94 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $62.98 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $62.34 | 2024 | Qelbree |
| Nestle Healthcare Nutrition INC. | $51.43 | 2022 | |
| Exact Sciences Corporation | $45.63 | 2024-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $40.72 | 2025 | Inspire |
| Daiichi Sankyo INC. | $40.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.02 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36.46 | 2020 | |
| Abbott Laboratories | $34.08 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.90 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $23.92 | 2021 | |
| Axsome Therapeutics, INC. | $23.04 | 2023 | Auvelity |
| Sanofi Pasteur INC. | $17.23 | 2022 | |
| Astellas Pharma US INC | $15.52 | 2023 | Veozah |
| Mayne Pharma Commercial LLC | $14.95 | 2023 | |
| Organon LLC | $14.53 | 2021 | |
| Scynexis, INC. | $14.20 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.11 | 2021 | |
| Mylan Specialty L.P. | $13.75 | 2020 | |
| Amgen INC. | $12.79 | 2020 | |
| Radius Health, INC. | $12.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.05 | 2021 | |
| Inogen, INC. | $2.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.